{
    "clinical_study": {
        "@rank": "102453", 
        "arm_group": {
            "arm_group_label": "Cortexolone 17\u03b1-Propionate", 
            "arm_group_type": "Experimental", 
            "description": "Topical cream, 1.0% concentration, applied every twelve hours"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis\n      suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied\n      every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older."
        }, 
        "brief_title": "An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has moderate to severe facial acne vulgaris as determined by the\n             Investigator's Global Assessment (IGA) and obvious acne on the chest and/or back at\n             study start.\n\n          -  Subject has facial acne vulgaris (including the nose) with a minimum number of\n             inflammatory lesions (papules, pustules, and nodules/cysts) and a minimum number of\n             non-inflammatory lesions (open and closed comedones) at study start.\n\n          -  Females must be post-menopausal, surgically sterile or using highly effective birth\n             control methods with a negative urine pregnancy test (UPT) at study start.\n\n          -  Subject must be in general good health in the opinion of the investigator, with\n             normal renal function, based on screening physical examination, medical history, and\n             clinical laboratory values.\n\n        Exclusion Criteria:\n\n          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.\n\n          -  Subject is 12-20 years of age and has a Body Mass Index (BMI) for age percentile >\n             85%.\n\n          -  Subject is > 20 years of age and has a BMI > 32.0 kg/m2.\n\n          -  Subject has used tobacco, smoking cessation products, or products containing nicotine\n             within three months prior to study start.\n\n          -  Except for the use of contraceptives, subject has used any prescription drug or\n             herbal product within 14 days prior to dosing, any non-prescription drug or vitamin\n             or mineral supplements within 7 days prior to study start; any known enzyme-inducer,\n             enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint\n             solvents or pesticides within 30 days of study start.\n\n          -  Subject has used topical anti-acne medications containing retinoids such as\n             tazarotene, adapalene or tretinoin, within four weeks of study start.\n\n          -  Subject has used the following systemic anti-acne medications: antibiotics within two\n             weeks of study start, spironolactone within four weeks of study start, or retinoid\n             therapy within three months of study start.\n\n          -  Subject has any skin or medical condition, including facial hair that could interfere\n             with the evaluation of the test article or requires the use of interfering topical or\n             systemic therapy.\n\n          -  Subject has the need or plans to be exposed to artificial tanning devices or\n             excessive sunlight during the study.\n\n          -  Subject has used light treatments, microdermabrasion or chemical peels to the face,\n             chest and back within eight weeks of study start.\n\n          -  Subject cannot avoid any type of strenuous exercise (swimming, running, team sports,\n             etc.,) or the use of hot tubs/saunas from study start to the end of the study.\n\n          -  Subject has received an investigational drug or been treated with an investigational\n             device within 30 days prior to study start.\n\n          -  Subject is currently enrolled in an investigational drug or device study.\n\n          -  Subject has used topical corticosteroids (including inhaled and intranasal\n             corticosteroids) within two weeks of study start.\n\n          -  Subject has used systemic corticosteroids (including intramuscular and intralesional\n             injections) within four weeks of study start.\n\n          -  Subject has an irregular sleep schedule or works night shifts.\n\n          -  Subject has experienced significant blood loss within 60 days or has donated plasma\n             within 72 hours prior to study start.\n\n          -  Subject tests positive at Screening for human immunodeficiency virus (HIV) or is\n             known to be seropositive for HIV.\n\n          -  Subject tests positive at Screening for hepatitis B surface antigen, hepatitis C\n             antibody or has a history of a positive result.\n\n          -  Subject had major surgery within 30 days prior to study start or plans to have\n             surgery during the study.\n\n          -  Subject has participated in a previous CB-03-01 study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831960", 
            "org_study_id": "171-7151-202"
        }, 
        "intervention": {
            "arm_group_label": "Cortexolone 17\u03b1-Propionate", 
            "intervention_name": "cortexolone 17\u03b1-propionate", 
            "intervention_type": "Drug", 
            "other_name": "CB-03-01"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Intrepid", 
            "cortexolone", 
            "cortexolone 17\u03b1-propionate", 
            "anti-androgen"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boise", 
                        "country": "United States", 
                        "state": "Idaho"
                    }, 
                    "name": "Northwest Clinical Trials, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carmel", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Shideler Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clinton Township", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Michigan Center for Research Corp."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17\u03b1-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris", 
        "overall_official": {
            "affiliation": "Therapeutics, Inc.", 
            "last_name": "Syd Dromgoole, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level \u2264 18 \u03bcg/dL at Day 14.", 
                "measure": "Change in HPA Axis Response to Cosyntropin", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "description": "Concentration-time profiles of cortexolone 17\u03b1-propionate and its metabolite, cortexolone, in plasma.", 
                "measure": "Change in PK profiles of cortexolone 17\u03b1-propionate and cortexolone", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Intrepid Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intrepid Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}